DOT1L and acute myeloid leukemia: Therefore, combinations of Menin inhibitors with other chromatin regulators such as DOT1L, PRC2 complex, and CDK4/6 inhibitors and with intensive chemotherapy or less toxic Ven/Aza regimens are being tested in clinical trials for the treatment of AML [96].